CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Guangzhou LBP Medicine Scnc&Tech Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Guangzhou LBP Medicine Scnc&Tech Co Ltd
No. 2, Kexin Street, Fengxin Road
Science City, Huangpu District
Phone: +86 2032210051p:+86 2032210051 GUANGZHOU, GNG  510663  China Ticker: 688393688393
Business Summary
Guangzhou LBP Medicine Science & Technology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of in vitro diagnostic reagents and instruments. The Company’s main products are pathological diagnostic reagents and instruments, covering three major technology platforms for cytological diagnosis, molecular diagnosis and immunodiagnosis, including LBP series, IHC series, PCR series and FISH series, such as integrated slide and dyeing machine, liquid-based cell and microorganism processing, preservation reagents, automatic nucleic acid molecular hybridization instrument, automatic slide processing system and immunochromogenic reagents, etc. Its products are mainly used in pathological diagnosis of tumors. The Company operates its businesses within the domestic market and to overseas markets.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
3845 Electromedical and electrotherapeutic apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager XiangtingCai 59 3/1/2014 3/1/2014
Chief Financial Officer QuannengHou 40 5/1/2022 5/1/2022
Deputy General Manager, Director of Research Institute, Director ShaoyuChen 41 12/1/2020 12/1/2020
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 907 (As of 12/31/2023)
Outstanding Shares: 93,567,699 (As of 9/30/2024)
Shareholders: 8,310
Stock Exchange: SHA
Fax Number: +86 2032290284


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024